Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2013

Open Access 01-12-2013 | Erratum

Erratum to: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

Authors: Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frederic Lehmann, Neil Spector, Junping Wei, Takuya Osada, H Kim Lyerly, Michael A Morse

Published in: Journal of Translational Medicine | Issue 1/2013

Login to get access

Excerpt

In our original manuscript [1], the corresponding author, Michael A Morse, was missed from the authors’ list. Therefore the correct author list should be: …
Literature
1.
Hamilton : Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion. J Transl Med. 2012, 10: 28-10.1186/1479-5876-10-28.PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Authors
Erika Hamilton
Kimberly Blackwell
Amy C Hobeika
Timothy M Clay
Gloria Broadwater
Xiu-Rong Ren
Wei Chen
Henry Castro
Frederic Lehmann
Neil Spector
Junping Wei
Takuya Osada
H Kim Lyerly
Michael A Morse
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-11-82

Other articles of this Issue 1/2013

Journal of Translational Medicine 1/2013 Go to the issue

Research

Functional effect of Saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report

Research

MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab

Research

Adipose stromal cells primed with hypoxia and inflammation enhance cardiomyocyte proliferation rate in vitro through STAT3 and Erk1/2

Research

Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome

Methodology

Implementation of the CDC translational informatics platform - from genetic variants to the national Swedish Rheumatology Quality Register

Research

A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits